[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369872-105":59,"doc-detail-369872-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrated-in-silico-and-experimental-validation-of-antrocin-as-a-plant-derived-multi-target-therapeutic-for-brafmekpi3k-driven-colorectal-cancer","Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer","","Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide, with resistance to targeted therapies creating a major clinical challenge. This study integrates computational screening and laboratory experiments to identify Antrocin, a natural sesquiterpene lactone, as a multi-target inhibitor of the BRAF/MEK/PI3K oncogenic pathway in CRC. Bioinformatics analyses evaluate the frequency and clinical relevance of BRAF, MEK, and PI3K alterations. Molecular docking and drug-likeness/ADME predictions support Antrocin’s binding potential and candidate-like properties. In vitro and in vivo validations show reduced CRC growth, migration, and pathway signaling, alongside effects on the tumor microenvironment, indicating promise against therapy resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-in-silico-and-experimental-validation-of-antrocin-as-a-plant-derived-multi-target-therapeutic-for-brafmekpi3k-driven-colorectal-cancer/369872/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-in-silico-and-experimental-validation-of-antrocin-as-a-plant-derived-multi-target-therapeutic-for-brafmekpi3k-driven-colorectal-cancer/369872.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is Antrocin proposed to do in this colorectal cancer study?","Question",{"text":112,"@type":113},"Antrocin is proposed as a plant-derived multi-target therapeutic that inhibits the BRAF/MEK/PI3K oncogenic pathway in colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which computational resources were used to analyze BRAF/MEK/PI3K alterations?",{"text":117,"@type":113},"Public datasets and web tools were used, including TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental evidence supports Antrocin’s anti-cancer potential?",{"text":121,"@type":113},"In vitro assays in HCT116 and RKO cells show reduced viability, spheroid formation, and migration, with lowered expression of the BRAF/MEK/PI3K signaling pathway, and preclinical xenografts show delayed tumor growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369872,1791292712,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nIntegrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for  \nBRAF/MEK/PI3K-Driven Colorectal Cancer  \nJian-Syun Chen 1,2, Chioma Grace Enwolo-Chibueze 3, Harold Arnold Chinyama 4, Cheng-Ta Lai 1,2, Ifeyinwa Chioma Ezeala 5, Po-Yang Huang 6, Alexander T. H. Wu 6,7,8,9 and Yan-Jiun Huang 10,11,12, *  \nAcademic Editors: Manuel Aureliano, Juan Llopis and Agnieszka Scibior Received: 17 July 2025  \nRevised: 1 September 2025  \nAccepted: 2 September 2025  \nPublished: 9 September 2025  \nCitation: Chen, J.-S.; EnwoloChibueze, C.G.; Chinyama, H.A.; Lai, C.-T.; Ezeala, I.C.; Huang, P.-Y.; Wu, A.T.H.; Huang, Y.-J. Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived  \nMulti-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer. Int. J. Mol. Sci. 2025, 26, 8780. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms26188780](10.3390/ijms26188780)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Division of Colon and Rectal Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan; [manchette.4320@mmh.org.tw](manchette.4320@mmh.org.tw) (J.-S.C.); [iamctlai.4987@mmh.org.tw](iamctlai.4987@mmh.org.tw) (C.-T.L.)  \n2 Department of Medicine, MacKay Medical University, New Taipei City 252005, Taiwan  \n3 Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; [m654113004@tmu.edu.tw](m654113004@tmu.edu.tw)  \n4 Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; [d610113001@tmu.edu.tw](d610113001@tmu.edu.tw)  \n5 Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Nsukka 410001, Nigeria; [ifeyinwa.adaka@unn.edu.ng](ifeyinwa.adaka@unn.edu.ng)  \n6 The Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; [boyang0321@gmail.com](boyang0321@gmail.com) (P.-Y.H.); [chaw1211@tmu.edu.tw](chaw1211@tmu.edu.tw) (A.T.H.W.)  \n7 Clinical Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan  \n8 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan  \n9 Taipei Heart Institute, Taipei Medical University, Taipei 11031, Taiwan  \n10 Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan  \n11 Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan  \n12 Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan  \n* Correspondence: [d621108006@tmu.edu.tw](d621108006@tmu.edu.tw)  \nAbstract  \nColorectal cancer (CRC) remains a leading cause of cancer-related death worldwide, with resistance to targeted therapies presenting a significant clinical challenge. This study combines computational and experimental methods to identify and validate Antrocin, a natural sesquiterpene lactone, as a potential multi-target inhibitor of the BRAF/MEK/PI3Koncogenic pathway in CRC. Differential gene expression and mutational analyses were performed using public datasets (TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal) to assess the prevalence and clinical significance of BRAF, MEK, and PI3K alterations in CRC. In silico molecular docking, using AutoDock Vina, predicted strong binding affinities of Antrocin to BRAF (∆G = −8.5 kcal/mol), MEK (∆G = −7.3 kcal/mol),","cbCaiaPKPnSHee9s","https://ap.wps.com/l/cbCaiaPKPnSHee9s","pdf",6926003,31,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results\n## In silico analyses and docking\n## In vitro validation\n## In vivo xenograft findings\n# Discussion\n# Conclusion","[{\"question\":\"What is Antrocin proposed to do in this colorectal cancer study?\",\"answer\":\"Antrocin is proposed as a plant-derived multi-target therapeutic that inhibits the BRAF/MEK/PI3K oncogenic pathway in colorectal cancer.\"},{\"question\":\"Which computational resources were used to analyze BRAF/MEK/PI3K alterations?\",\"answer\":\"Public datasets and web tools were used, including TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal.\"},{\"question\":\"What experimental evidence supports Antrocin’s anti-cancer potential?\",\"answer\":\"In vitro assays in HCT116 and RKO cells show reduced viability, spheroid formation, and migration, with lowered expression of the BRAF/MEK/PI3K signaling pathway, and preclinical xenografts show delayed tumor growth.\"}]","Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer | PDF",1790185000,78,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/c8be28435ced3b62e7184d434e16c716.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/010c4fcab7b47cda34f3beefd81fcad7.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/8fe00f46bd5556fcb34496a431938001.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/1a5b2260065ac625c811c150e8107578.webp",980,1385]